[go: up one dir, main page]

WO2009118706A2 - Traitement d’infections helminthiques - Google Patents

Traitement d’infections helminthiques Download PDF

Info

Publication number
WO2009118706A2
WO2009118706A2 PCT/IB2009/051269 IB2009051269W WO2009118706A2 WO 2009118706 A2 WO2009118706 A2 WO 2009118706A2 IB 2009051269 W IB2009051269 W IB 2009051269W WO 2009118706 A2 WO2009118706 A2 WO 2009118706A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
treatment
active ingredients
praziquantel
mebendazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/051269
Other languages
English (en)
Other versions
WO2009118706A9 (fr
WO2009118706A3 (fr
Inventor
Charles George Scheepers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRI LAZ MEDS Pty Ltd
Original Assignee
TRI LAZ MEDS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRI LAZ MEDS Pty Ltd filed Critical TRI LAZ MEDS Pty Ltd
Publication of WO2009118706A2 publication Critical patent/WO2009118706A2/fr
Publication of WO2009118706A3 publication Critical patent/WO2009118706A3/fr
Publication of WO2009118706A9 publication Critical patent/WO2009118706A9/fr
Anticipated expiration legal-status Critical
Priority to ZA2011/00468A priority Critical patent/ZA201100468B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides

Definitions

  • THIS INVENTION relates to the treatment of helminthic infections. It relates more specifically to a composition for use in the treatment of helminthic infections and the use of the composition in the manufacture of a medicament for the treatment of a subject with a helminthic infection. It relates also to a medicinal product for use in the treatment of helminthic infections.
  • composition for use in the treatment of helminthic infections in human subjects which includes a combination of the following activate ingredients in the following percentages by mass:
  • the ingredients may be present in the composition in the following percentages by mass:
  • the composition may be provided in a dosage form comprising approximately 338mg of the composition for administering to persons aged 6-12 years, 675mg to persons aged 13-19 years and 1013mg to persons aged 20 years and older.
  • the dosage form may be in the form of one or more pressed tablets of the composition.
  • compositions for use in a method of treatment of a human subject with a helminthic infection including a combination of the following active ingredients in the following percentages by mass:
  • the ingredients may be present in the composition in the following percentages by mass:
  • composition as defined and described hereinabove in accordance with the first aspect of the invention, in the manufacture of a medicament for the treatment of a human subject with a helminthic infection.
  • a medicinal product for use in the treatment of helminthic infections in human subjects which includes the following active ingredients in the following percentages by mass:
  • the package may include a number of compartments, each ingredient being held in a different one of the compartments.
  • Each active ingredient may be in the form of a pressed tablet.
  • a medicinal product for use in a method of treatment of a human subject with a helminthic infection, the medicinal product being equivalent to the medicinal product as described and defined hereinabove in accordance with the fourth aspect of the invention, and said method comprising administering an oral dose of each active ingredient to the subject.
  • Example 1 Example 1
  • composition in accordance with the first aspect of the invention is provided in a dosage form.
  • the composition comprises a combination of the following active ingredients in the following amounts:
  • the above ingredients are provided in the form of a pressed tablet. More particularly, the pressed tablet is prepared by providing the above active ingredients in powder form, mixing the ingredients together with a binding agent and moulding the ingredients under pressure to form the pressed tablet.
  • composition is used for the treatment of helminthic infections in human subjects by administering an oral dose of the composition to the subject.
  • the amount of the composition to be used in the treatment of a subject with a helminthic infection will vary according to the age or body mass of the subject. The applicant envisages that the following dosages will be administered to persons:
  • the active ingredients may each be provided in the form of a separate pressed tablet.
  • the invention extends to a medicinal product in the form of a package such as a blister pack which contains tablets of the active ingredients.
  • Example 2
  • Praziquantel [2-(Cyclohexylcarbonyl)-1 ,2,3,6,7,1 1 b-hexahydro ⁇ HH-pyrazino (2,1 -a) isoquinolin-4-one] is an anthelminthic effective against tapeworm infections and against Schistosome (S. haematobium, S. mansoni and S. japonicium).
  • Niclosamide [5-Chloro-N-(2-chloro-4-nitrophenyl)-2 hydroxybenzamide] is an anthelminthic effective against a number of tapeworms, including the beef tapeworm (Taenia saginata), the pork tapeworm (T.solium,) the fish tapeworm (Diphyllobothrium latum) and the dwarf tapeworm (Hymenolepis nana).
  • Mebendazole (5-Benzoyl-1 H-benzimidazol-2-yl) carbamic acid methyl ester] is an anthelminthic effective against threadworms (Enterobius), round worms (Ascaris), whipworms (Tricharis) and hook worms (Ancylostems and Necator). It is also effective against tapeworms and strangyloid worms.
  • helminthic infections are believed to significantly suppress the immune mechanisms of the human body thereby further compromising the immune systems of subjects with already compromised immune systems.
  • Such helminthic infections are particularly prevalent in developing countries in which large numbers of people live under poor living conditions and sanitation and where poor nutrition, poverty and lack of education are further contributing factors to the relatively high incidence of helminthic infections.
  • the composition and medicinal product as defined and described hereinabove are thus specifically intended for use as complementary medicaments in the treatment of subjects with compromised immune systems.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour utilisation dans le traitement d’infections helminthiques chez des sujets humains, la composition comprenant une combinaison des principes actifs suivants aux pourcentages en masse suivants : 33 % de praziquantel, 45 % de mébendazole et 22 % de niclosamide. La composition est particulièrement adaptée pour utilisation dans le traitement de sujets humains ayant un système immunitaire déprimé.
PCT/IB2009/051269 2008-03-26 2009-03-26 Traitement d’infections helminthiques Ceased WO2009118706A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA2011/00468A ZA201100468B (en) 2008-03-26 2011-01-18 The treatment of helminthic infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200802695 2008-03-26
ZA2008/02695 2008-03-26

Publications (3)

Publication Number Publication Date
WO2009118706A2 true WO2009118706A2 (fr) 2009-10-01
WO2009118706A3 WO2009118706A3 (fr) 2009-12-03
WO2009118706A9 WO2009118706A9 (fr) 2010-01-14

Family

ID=41114398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/051269 Ceased WO2009118706A2 (fr) 2008-03-26 2009-03-26 Traitement d’infections helminthiques

Country Status (2)

Country Link
WO (1) WO2009118706A2 (fr)
ZA (1) ZA201100468B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051633A1 (fr) * 2010-10-15 2012-04-19 Tri Laz Meds Sa (Pty) Ltd Traitement d'infections helminthiques
WO2013093790A1 (fr) * 2011-12-22 2013-06-27 Shoket Latief Composition pour réduire une charge virale de vih comprenant du praziquantel, du niclosamide et de l'albendazole

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATZ, M.: 'Anthelmintics. Current Concepts in the Treatment of Helminthic Infections.' DRUGS vol. 32, no. 4, October 1986, pages 358 - 371 *
PAMPORI, N. A. ET AL.: 'Cotugnia digonopora: carbohydrate metabolism and effect of anthelmintics on immature worms.' JOURNAL OF HELMINTHOLOGY vol. 58, no. 1, March 1984, pages 39 - 47 *
SHARMA, P.: 'Broad-action anthelminthics against intestinal helminthiases.' TROPICAL. GASTROENTEROLOGY vol. 4, no. 3, July 1983, pages 137 - 154 *
VOLKHEIMER, G.: 'Intestinale Helminthosen - Praxisproblem des. Gastroenterologen. (Intestinal helminthiasis--general practice problem of the gastroenterologist)' ZEITSCHRIFT FUR GASTROENTEROLOGIE vol. 34, no. 9, September 1996, pages 534 - 541 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051633A1 (fr) * 2010-10-15 2012-04-19 Tri Laz Meds Sa (Pty) Ltd Traitement d'infections helminthiques
WO2013093790A1 (fr) * 2011-12-22 2013-06-27 Shoket Latief Composition pour réduire une charge virale de vih comprenant du praziquantel, du niclosamide et de l'albendazole

Also Published As

Publication number Publication date
WO2009118706A9 (fr) 2010-01-14
WO2009118706A3 (fr) 2009-12-03
ZA201100468B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
TW200412960A (en) Potent inhibitor of HCV serine protease
JP2017514911A5 (fr)
CN105380941A (zh) 苯酞类化合物药物用途及其医药组合物
MX2024015351A (es) Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
AU2004283047B2 (en) Pharmaceutical composition comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
JP3170855B2 (ja) イブプロフェン含有解熱鎮痛剤
WO2009118706A2 (fr) Traitement d’infections helminthiques
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
EP3200793B1 (fr) Comprimés sublinguaux à désintégration rapide de sulfate d'atropine, procédés de fabrication, et procédé pour leur utilisation pour le traitement d'une toxicité aiguë aux organophosphates
WO2013093790A1 (fr) Composition pour réduire une charge virale de vih comprenant du praziquantel, du niclosamide et de l'albendazole
US5432187A (en) Benzimidazole anthelmintic in the treatment of microsporidial infections
WO2017141137A1 (fr) Composition et forme posologique pour réduction de la charge virale en vih
US20170020946A1 (en) Analgesic compositions and methods of use
CN107648249B (zh) 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
Nugrahaningsih et al. Chloroquine and hydroxychloroquine for COVID-19 treatment
CN104906501A (zh) 治疗银屑病的中药组分组合物
EA049592B1 (ru) СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2)
WO2012051633A1 (fr) Traitement d'infections helminthiques
Sainaghi et al. Jason Lickliter1, Xin Yang2, Jiawang Guo2, Wubin Pan2 and Zheng Wei2, 3
WO2021242134A1 (fr) Procédé de traitement d'infections virales par arn, y compris le covid-19 (sars-cov-2)
CA2963525C (fr) Comprimes sublinguaux a desintegration rapide de sulfate d'atropine, procedes de fabrication, et procede pour leur utilisation pour le traitement d'une toxicite aigue aux organophosphates
US20200155532A1 (en) Method for treating viral infections with loperamide
WO1997000072A1 (fr) Composition anti-inflammatoire/analgesique

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09724528

Country of ref document: EP

Kind code of ref document: A2